Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial.

PubWeight™: 0.91‹?›

🔗 View Article (PMC 4339281)

Published in Target Oncol on May 10, 2013


Johnny Kao1, Chien-Ting Chen, Charles C L Tong, Stuart H Packer, Myron Schwartz, Shu-Hsia Chen, Max W Sung

Author Affiliations

1: Department of Radiation Oncology, Good Samaritan Hospital Medical Center, 1000 Montauk Highway, West Islip, NY, 11795, USA,

Articles citing this

Clinical Predictors of Survival for Patients with Stage IV Cancer Referred to Radiation Oncology. PLoS One (2015) 2.02

Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications. Front Immunol (2015) 0.92

The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy. Oncoimmunology (2015) 0.83

A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma. Br J Cancer (2014) 0.82

Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials. Onco Targets Ther (2014) 0.80

Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy. Clin Cancer Res (2015) 0.80

Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancer. Front Oncol (2013) 0.80

Combining targeted agents with modern radiotherapy in soft tissue sarcomas. J Natl Cancer Inst (2014) 0.76

Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer. Oncologist (2016) 0.76

Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol (2017) 0.75

Sunitinib: the antiangiogenic effects and beyond. Onco Targets Ther (2016) 0.75

Survival and Control Prognosticators of Recurrent Gynecological Malignancies of the Pelvis and Para-aortic Region Treated with Stereotactic Body Radiation Therapy. Front Oncol (2016) 0.75

Effects of combined sunitinib and extracranial stereotactic radiotherapy on bone marrow hematopoiesis. Oncol Lett (2016) 0.75

Articles cited by this

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39

A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol (2008) 14.74

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med (2009) 12.92

Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46

A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med (1990) 7.92

Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet (2004) 7.78

Sunitinib: from rational design to clinical efficacy. J Clin Oncol (2007) 7.26

Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA (2011) 6.14

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10

Oligometastases. J Clin Oncol (1995) 4.95

Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol (2009) 4.59

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18

Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol (2009) 3.00

Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol (2007) 2.80

Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol (2009) 2.78

Oligometastases revisited. Nat Rev Clin Oncol (2011) 2.42

Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature (1998) 2.29

Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys (2011) 2.03

SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res (2003) 2.00

The concurrent chemoradiation paradigm--general principles. Nat Clin Pract Oncol (2007) 1.98

Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys (2001) 1.96

A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer (2008) 1.78

Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer (2011) 1.70

An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res (2008) 1.68

CyberKnife frameless stereotactic radiosurgery for spinal lesions: clinical experience in 125 cases. Neurosurgery (2004) 1.32

Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer (2009) 1.28

Local surgical, ablative, and radiation treatment of metastases. CA Cancer J Clin (2009) 1.28

Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol (2010) 1.25

Normal tissue toxicity after small field hypofractionated stereotactic body radiation. Radiat Oncol (2008) 1.21

Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol (2004) 1.09

Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol (2009) 1.07

Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS One (2012) 0.95

Articles by these authors

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20

Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res (2006) 7.02

Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05

Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51

Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50

The terminology issue for myeloid-derived suppressor cells. Cancer Res (2007) 4.37

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35

Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03

Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18

Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res (2005) 2.91

Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood (2007) 2.65

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42

Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39

A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32

Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (2004) 2.29

Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18

Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells. Eur J Immunol (2008) 2.05

Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res (2009) 2.02

Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98

Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl (2004) 1.88

Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res (2004) 1.85

MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77

Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development. Nature (2012) 1.75

Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells. Stem Cells (2010) 1.75

Paired immunoglobin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells. Immunity (2011) 1.72

IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol (2010) 1.66

Resection of hepatocellular carcinoma with macroscopic vascular invasion. Ann Surg Oncol (2013) 1.65

Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice. J Clin Invest (2013) 1.57

Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice. J Clin Invest (2010) 1.55

Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg (2015) 1.53

Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol (2002) 1.52

Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-1alpha-mediated stellate cell activation. Hepatology (2009) 1.48

The beneficial impact of temporary porto-caval shunt in orthotopic liver transplantation: a single center analysis. Transpl Int (2010) 1.48

Intrahepatic cholangiocarcinoma: new insights in pathology. Semin Liver Dis (2011) 1.46

De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci (2006) 1.45

Fulminant and fatal gas gangrene of the stomach in a healthy live liver donor. Liver Transpl (2004) 1.44

Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res (2012) 1.44

Myeloid-derived suppressor cells prevent type 1 diabetes in murine models. J Immunol (2010) 1.38

An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis. J Clin Invest (2002) 1.35

Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer (2009) 1.28

Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol (2010) 1.25

Transoral robotic resection and reconstruction for head and neck cancer. Laryngoscope (2011) 1.24

NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int J Cancer (2004) 1.17

OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol Ther (2002) 1.13

Polarization and reprogramming of myeloid-derived suppressor cells. J Mol Cell Biol (2013) 1.12

DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunity. Cell Biosci (2011) 1.11

Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest (2012) 1.09

Feasibility and preliminary accuracy of high-resolution imaging of the liver and pancreas using FNA compatible microendoscopy (with video). Gastrointest Endosc (2012) 1.09

Intravascular epithelioid hemangioendothelioma of the inferior vena cava: case report of an unusual and unpredictable vascular tumor. Cardiovasc Pathol (2008) 1.09

Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J Immunol (2012) 1.05

Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Cancer (2012) 1.05

Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy. Cancer Res (2013) 1.04

Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl (2009) 1.02

Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. Cancer (2011) 1.01

Second hepatic resection for recurrent hepatocellular cancer: a Western experience. J Hepatol (2010) 1.00

Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. Oncologist (2005) 0.96

Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS One (2012) 0.95

Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one monosodium phosphate (CHM-1-P-Na) as a potent antitumor agent. J Med Chem (2010) 0.93

Liver transplantation for neuroendocrine tumors. J Gastrointest Surg (2004) 0.93

Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation. J Immunol (2004) 0.93

FDG PET with contrast-enhanced CT: a critical imaging tool for laryngeal carcinoma. Radiographics (2010) 0.92

Cholangiolocellular carcinoma: an innocent-looking malignant liver tumor mimicking ductular reaction. Semin Liver Dis (2011) 0.91

Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation. Am J Transplant (2004) 0.91

Myeloid-derived suppressor cells: natural regulators for transplant tolerance. Hum Immunol (2010) 0.91

Recurrence of hepatocellular carcinoma after liver transplantation: is immunosuppression a factor? Liver Transpl (2005) 0.90

The incidence and significance of late acute cellular rejection (>1000 days) after liver transplantation. Clin Transplant (2004) 0.88

Resection of hepatocellular carcinoma without cirrhosis. Ann Surg (2012) 0.87

Treatment strategies for hepatocellular carcinoma in cirrhosis. J Gastrointest Surg (2003) 0.87

Trefoil factor-3 expression in human colon cancer liver metastasis. Clin Exp Metastasis (2008) 0.87

Retracted Liver functional reserve estimation: state of the art and relevance to local treatments. Oncology (2010) 0.86

In situ recruitment of antigen-presenting cells by intratumoral GM-CSF gene delivery. Cancer Immunol Immunother (2003) 0.85

Establishing an international training program for surgical residents. J Surg Educ (2007) 0.85

Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation. Oncol Rep (2011) 0.84

Cancer history and other personal factors affect quality of life in patients with hepatitis C. Health Qual Life Outcomes (2005) 0.84

IFN-gamma sensitization of prostate cancer cells to Fas-mediated death: a gene therapy approach. Mol Ther (2003) 0.84

Primary hepatic signet ring cell neuroendocrine tumor: a case report with literature review. Semin Liver Dis (2010) 0.84

Carcinoma ex microcystic adenoma of the pancreas: a report of a novel form of malignancy in serous neoplasms. Am J Surg Pathol (2012) 0.83

R-Ras is required for murine dendritic cell maturation and CD4+ T-cell priming. Blood (2011) 0.83

On the conduction pathway for protons in nanocrystalline yttria-stabilized zirconia. Phys Chem Chem Phys (2009) 0.83

Liver functional reserve estimation: state of the art and relevance for local treatments: the Western perspective. J Hepatobiliary Pancreat Sci (2009) 0.83

A functional recombinant human 4-1BB ligand for immune costimulatory therapy of cancer. J Immunother (2011) 0.82

Prognostic clinicopathologic factors in longitudinally followed patients with metastatic small bowel carcinoid tumors. Pancreas (2011) 0.82

Epstein-Barr virus and human hepatocellular carcinoma. Cancer Lett (2003) 0.82

Adult-adult living donor liver transplantation. J Gastrointest Surg (2004) 0.82

Advancements in immune tolerance. Adv Drug Deliv Rev (2007) 0.82

Treatment of recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl (2011) 0.82

Liver transplantation for hepatocellular carcinoma. Hepatol Res (2007) 0.81

The role of liver resection at the time of secondary cytoreduction in patients with recurrent ovarian cancer. Int J Gynecol Cancer (2014) 0.81

Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there. Semin Liver Dis (2006) 0.81